<code id='CF46C0567A'></code><style id='CF46C0567A'></style>
    • <acronym id='CF46C0567A'></acronym>
      <center id='CF46C0567A'><center id='CF46C0567A'><tfoot id='CF46C0567A'></tfoot></center><abbr id='CF46C0567A'><dir id='CF46C0567A'><tfoot id='CF46C0567A'></tfoot><noframes id='CF46C0567A'>

    • <optgroup id='CF46C0567A'><strike id='CF46C0567A'><sup id='CF46C0567A'></sup></strike><code id='CF46C0567A'></code></optgroup>
        1. <b id='CF46C0567A'><label id='CF46C0567A'><select id='CF46C0567A'><dt id='CF46C0567A'><span id='CF46C0567A'></span></dt></select></label></b><u id='CF46C0567A'></u>
          <i id='CF46C0567A'><strike id='CF46C0567A'><tt id='CF46C0567A'><pre id='CF46C0567A'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:56

          Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

          advertisement

          For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          focus

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Abortion pill Supreme Court ruling could impact entire drug industry
          Abortion pill Supreme Court ruling could impact entire drug industry

          AnnaMoneymaker/GettyImagesWASHINGTON—TheSupremeCourtonTuesdaywillhearopeningargumentsinanabortionmed

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Study says nonprofit hospitals fall short in charity care spending

          AdobeAnewstudyofhospitals’charitycarespendingsuggestsnonprofithospitalsreallyaren’tthatdifferentfrom